argenx SE
(NASDAQ : ARGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 0.02%55.246.5%$162.29m
CTLTCatalent, Inc. -0.87%72.742.1%$126.75m
JAZZJazz Pharmaceuticals Plc 0.13%109.752.4%$111.48m
VRXValeant Pharmaceuticals International, Inc. -0.43%18.3414.1%$107.92m
BHCBausch Health Cos., Inc. -0.43%18.340.0%$80.86m
UTHRUnited Therapeutics Corp. -0.55%120.3314.3%$73.10m
ICPTIntercept Pharmaceuticals, Inc. 1.23%47.0916.8%$61.07m
AXSMAxsome Therapeutics, Inc. -3.50%80.971.9%$52.73m
ZGNXZogenix, Inc. 0.41%29.197.5%$50.72m
PRGOPerrigo Co. Plc 0.64%55.186.8%$49.09m
MYOKMyoKardia, Inc. 0.29%94.111.8%$46.94m
AMRNAmarin Corp. Plc -1.57%6.921.6%$43.50m
ARGXargenx SE 0.38%228.720.0%$40.18m
PCRXPacira Biosciences, Inc. -1.45%52.3710.3%$40.00m
ICLRICON plc -0.55%166.914.3%$38.56m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.